Interestingly, our results from DREBIC analysis and from the experimental drug treatment data indicate that thyroid cancer is substantially sensitive to MEK inhibitors (even more than PDAC and melanoma). This evidence concerns the gene MAP2K7 and thyroid gland carcinoma.